Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats

Pharmazie

Volumn 65, Issue 7, 2010, Pages 510-514

  Li, C ^a,c   Lee, M Y ^b   Choi, Jun Shik ^c  

^a YANBIAN UNIVERSITY   (China)

^b BK21 Project Team ^*  (South Korea)

^c Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P INHIBITOR; LORATADINE; SILIBININ;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; FIRST PASS EFFECT; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METABOLIC INHIBITION; NONHUMAN; RAT; SMALL INTESTINE;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUORESCENT DYES; HALF-LIFE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; INJECTIONS, INTRAVENOUS; LORATADINE; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; SILYMARIN;

EID: 77955353195     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0502     Document Type: Article

References (34)

1. Amini H, Ahmadiani A (2004) Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 809: 227-230. (Pubitemid 39094698)
2. Bradley CM, Nicholson AN (1987) Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 32: 419-421. (Pubitemid 17077191)
3. Carr RA, Edmonds A, Shi H, Locke CS, Gustavson LE, Craft JC, Harris SI, Palmer R (1998) Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agents Chemother 42: 1176-1180. (Pubitemid 28227916)
4. Clissold SP, Sorkin EM, Goa KL (1989) Loratadine, a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37: 42-57. (Pubitemid 19086731)
5. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188-190. (Pubitemid 27218241)
6. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300: 1036-1045.
7. Cushnie TPT, Lamb AJ (2005) Antimicrobial activity of flavonoids. Inter J Antimicrobial Agents 26: 343-356.
8. Dixon RA, Steel CL (1999) Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trend Plant Sci 4: 394-400.
9. Dzubák P, Hajdúch M, Gazák R, Svobodová A, Psotová J, Walterová D, Sedmera P, Kren V (2006) New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem 14: 3793-3810.
10. Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, Zampaglione N (1987) Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 27: 694-698.
11. Ito K, Kusuhara H, Sugiyama Y (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption; theoretical approach. Pharm Res 16: 225-231.
12. Kaminsky LS, Fasco MJ (1991) Small intestinal cytochromes P450. Crit Rev Toxicol 21: 407-422.
13. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J National Cancer Institute 89: 556-566.
14. Kay GG, Berman B, Mockoviak SH, Morris CE, Reeves D, Starbuck V, Su-kenik E, Harris AG (1997) Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 157: 2350-2356.
15. Kosina P, Maurel P, UlrichováJ, Dvorák Z (2005) Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 19: 149-153.
16. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB (2000) Evaluation of the pha-rmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant ad-ministration of ketoconazole or cimetidine. Br J Clin Pharmacol 50: 581-589.
17. Li C, Kim CS,Yang JY, Park YJ, Choi JS (2008) Effects of roxithromycin on the pharmacokin-etics of loratadine after oral and intravenous administration of loratadine in rats. Eur J Drug Metab Pharmacokinet 33: 231-236.
18. Morazzoni P, BombardelliE(1995) Silybummarianum (fitoterapia). Fitoterapia 66: 3-42.
19. Philpot EE (2000) Safety of second generation antihistamines. Allerg Asthma Proc 21: 15-19.
20. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP, Maurel P (1990) Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 18: 711-719.
21. Prenner BM, Capano D, Harris AG (2000) Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: adouble-blind comparison with crossover treatment of nonresponders. Clin Ther 22: 760-769.
22. Ramaekers JG, Uiterwijk MM, O'Hanlon JF (1992) Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 42: 363-369.
23. Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61: 2035-2063.
24. Sutherland L, Ebner T, Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45: 295-301.
25. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142: 778-787.
26. Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87: 1322-1330.
27. Wang EJ, Casciano CN, Clement RP, Johnson WW (2001) Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispo 29: 1080-1083.
28. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 10: 1439-1443.
29. Wu JW, Lin LC, Tsai TH (2009) Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 121: 185-193.
30. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
31. Yin OQ, Shi X, Chow MS (2003) Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 796: 165-172.
32. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51: 165-172.
33. Zhao J, Lahiri-Chatterjee M, Sharma Y, Agarwal R (2000) Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 21: 811-816.
34. Zuber R, Modrianský M, Dvorák Z, Rohovský P, Ulrichová J, Simánek V, Anzenbacher P (2002) Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 16: 632-638.